Advertisement

Drugs

, Volume 22, Issue 2, pp 81–110 | Cite as

Triazolam: A Review of its Pharmacological Properties and Therapeutic Efficacy in Patients with Insomnia

  • G. E. Pakes
  • R. N. Brogden
  • R. C. Heel
  • T. M. Speight
  • G. S. Avery
Drug Evaluations

Summary

Synopsis

Triazolam1 is a triazolobenzodiazepine with hypnotic properties, advocated for use in acute or chronic insomnia, situational insomnia in hospitalised patients, and insomnia associated with other disease states. As triazolam has a relatively short half-life of about 2 to 3 hours in healthy subjects and has only 1 short acting active metabolite, α-hydroxytriazolam, it would seem more suitable as an hypnotic than longer acting drugs such as flurazepam, nitrazepam or flunitrazepam, particularly when residual sedative effects on the day after ingestion are undesirable. Thus, with usual hypnotic doses of triazolam (0.25 or 0.5mg) impairment of psychomotor and cognitive function is generally not carried over into the day after ingestion, although at doses of 1mg or greater, residual effects may appear. In short term comparative studies triazolam was clearly superior to a placebo, and was at least as effective as flurazepam, or other benzodiazepines such as nitrazepam or diazepam, in hastening sleep onset, reducing nocturnal awakenings, and increasing sleep duration. In other studies it was often superior to chloral hydrate, methyprylone or quinalbarbitone (secobarbital). In a small number of patients with chronic insomnia receiving extended treatment with triazolam in a clinical setting or in some sleep laboratory studies, no evidence of tolerance occurred; however, some evidence of reduced effect with repeated administration has been reported in one sleep laboratory study. Thus, a definitive statement about the likelihood of tolerance occurring on repeated administration is difficult to make at this time.

Pharmacodynamic Studies

Triazolam is a 1,4-benzodiazepine analogue. In hypnosis models in mice, triazolam was 2, 4 and 8 times more potent on a weight basis than flurazepam, nitrazepam and diazepam, respectively. In human sleep laboratory studies, triazolam, like other benzodiazepine hypnotics, caused dose-dependent effects on sleep stages in both healthy volunteers and insomniac patients, reducing stage ‘wake’ and stage 1 sleep, increasing stage 2 and usually having minimal effects on stages 3 and 4. Most sleep laboratory studies have not shown polygraphic evidence of tolerance (loss of initial stage ‘wake’ reduction) or rebound insomnia on abrupt withdrawal, but evidence of reduced effectiveness on repeated administration was reported in one such study. Further data on longer term use are thus needed before it can be clearly stated whether or not tolerance is likely to be a significant problem during chronic therapy. Like flurazepam 15mg, no or only slight depression of rapid eye movement (REM) sleep occurred after triazolam 0.25 or 0.5mg; however, a higher dose of 1mg may significantly reduce REM sleep, and cause REM rebound on withdrawal, as may occur with ‘higher’ doses of flurazepam.

In contrast to findings with flurazepam and nitrazepam, sleep stage alterations and EEG changes during short term administration of triazolam did not extend past the morning after ingestion. Similarly, impairment of performance of psychomotor and cognitive tests was significantly less in subjects 10 hours after taking triazolam 0.25 and 0.5mg than after flurazepam 15 and 30mg, nitrazepam 10mg, or quinalbarbitone 100mg.

Pharmacokinetics

Triazolam is rapidly absorbed following oral ingestion; after an oral dose of 0.88mg, peak plasma concentrations are reached after 1.3 hours. Triazolam is about 90 % bound to human plasma albumin. It is widely distributed to body tissues in monkeys. In man, triazolam is converted to 6 metabolites, of which one, a-hydroxytriazolam, has been stated to have 50 to 100% of the potency of the parent compound; however, the relative contribution of this minor metabolite to the clinical effects of the drug is unclear since this metabolite is present in the plasma primarily in its conjugated form. The plasma elimination half-life of triazolam is about 2.2 hours. After oral administration, triazolam is excreted in the urine (about 91%) and faeces (about 9 %), mainly as conjugates of the a-hydroxytriazolam and 4-hydroxy metabolites. There is no evidence that triazolam or any of its metabolites accumulate on repeated administration in patients with normal renal function.

Therapeutic Trials

A number of double-blind crossover controlled trials, involving mainly outpatient insomniacs taking triazolam 0.25 or 0.5mg for a single night, have shown triazolam to be superior to a placebo, often better than usual doses of chloral hydrate, methyprylone or quinalbarbitone, and at least as effective as flurazepam 15 or 30mg, nitrazepam or diazepam in hastening sleep onset, reducing nocturnal awakenings, and/or increasing sleep duration. In 3 longer term trials comparing triazolam with flurazepam, both drugs maintained their effectiveness for up to 84 nights of administration. In the only in-patient crossover study, comparing triazolam 0.5mg with flurazepam 30mg in psychiatric patients, both hypnotics were equally effective on all sleep parameters over 44 nights of use. In geriatric patients, triazolam 0.25 to 1 mg has produced sleep without the paradoxical agitation or impaired morning alertness that has sometimes been reported with flurazepam or nitrazepam. When compared with placebo in a 2-night double-blind crossover trial in elderly patients, triazolam 0.125mg appeared to induce faster sleep onset (15 minutes faster) and longer duration of sleep (0.5 hours longer), although nocturnal awakenings did not change. In an open 1-year study where triazolam 0.5 to 1mg was taken nightly by psychiatric patients, hypnotic efficacy was maintained with no evidence of tolerance, habituation, change in dream patterns, rebound insomnia, or apparent adverse drug interactions with antidepressant and antipsychotic drugs administered concomitantly. As in insomniac patients, in presurgical, postsurgical, and postpartum patients, triazolam 0.25 or 0.5mg was at least as effective for hypnotic use as flurazepam 30mg, nitrazepam 5mg or flunitrazepam 0.25 to 2mg. Thus, in presurgical patients, triazolam 0.5mg resulted in a sleep time of 6 to 8 hours in 8496 of patients, compared with 76%, 7296 and 3296 of those receiving flurazepam 30mg, nitrazepam 5mg, and placebo, respectively.

Side Effects

Triazolam has generally been well tolerated, and discontinuation of therapy has rarely been necessary. Residual drowsiness (‘hangover’) has been the most frequently reported side effect and, as is to be expected, it is dose-dependent, the incidence usually being no greater than with a placebo after a 0.25mg dose (5.7% for both), slightly higher after 0.5mg (8.1%), but about 4 times greater after 1 mg. Like flurazepam, other side effects, such as headache, dizziness, nervousness and dry mouth have occurred in less than 4% of patients on triazolam 0.25 and 0.5mg, and these have usually been mild. 2 cases of anterograde amnesia have been reported. Recent atypical reports in the Netherlands of a cluster of intolerable psychological changes has led the Dutch drug registry to temporarily suspend sale of triazolam in that country. However, further confirmation of these largely anecdotal reports will be needed before the side effect can be attributed solely to triazolam or to other causes. Such effects have not been reported in other countries.

Dosage

The usual dose range of triazolam is 0.25 to 0.5mg, taken at bedtime or shortly before. In chronic insomniacs transferred from long term therapy with other hypnotic agents, up to 1mg may be needed to produce satisfactory sleep. The 1mg dose usually should be reserved for hospitalised patients. In elderly patients, or those with a history of marked sensitivity, 0.125mg may suffice. Prior to receiving triazolam, as with all hypnotic agents, patients should be cautioned about the additive effects of other depressant drugs and alcohol, and the possibility of residual effects on performance the morning after ingestion.

Keywords

Triazolam Flunitrazepam Nitrazepam Flurazepam Chronic Insomnia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Albanus, L; Jonsson, M.; Sparf, B. and Vessman, J.: A study of the induction effect of phenobarbital, diazepam, and oxazepam in the dog (abstract). Acta Pharmacologica et Toxicologica 29(Suppl. 4): 55 (1971).Google Scholar
  2. Ayd, F.J. Jr; Barclay, W.R.; Callan, J.P.; Curran, W.J.; Gardner, E.A.; Greenblatt, D.J.; Ladimer, I.; LaPierre, Y.; Lehmann, H.E.; O’Donnell, T.J.; van Praag, H.M. and Shader, R.I.: Behavioural reactions to triazolam. Lancet 2: 1018 (1979).PubMedGoogle Scholar
  3. Bellantuono, C; Reggi, V.; Tognoni, G. and Garattini, S.: Benzodiazepines: Clinical pharmacology and therapeutic use. Drugs 19: 195–219 (1980).PubMedGoogle Scholar
  4. Bentel, H.: A comparative study between two new benzodiazepine hypnotics. South African Medical Journal 57: 769–770 (1980).PubMedGoogle Scholar
  5. Bond, A.J. and Lader, M.H.: Residual effects of hypnotics. Psychopharmacologia 25: 117–132 (1972).PubMedGoogle Scholar
  6. Bossier, D.: Etude a double insu comparant 0.25mg de triazolam et 5mg de nitrazepam chez des operes. Acta Therapeutica 3: 257–268 (1977).Google Scholar
  7. Bowen, A.J.: Comparative efficacy of triazolam, flurazepam and placebo in outpatient insomniacs. Journal of International Medical Research 6: 337–347 (1978).PubMedGoogle Scholar
  8. Boyd, E.L.; Knapp, R.B.; Remen, D. and Linet, O.I.: The comparison of the hypnotic activity of triazolam, diazepam, and placebo in inpatient insomniacs. West Virginia Medical Journal 72: 208 (1976).Google Scholar
  9. Braestrup, C. and Nielsen, M.: Benzodiazepine receptors. Arzneimittel-Forschung 30: 852–857 (1980).PubMedGoogle Scholar
  10. Breckenridge, A. and Orme, M.: Clinical implications of enzyme induction. Annals of the New York Academy of Sciences 179: 421–431 (1971).PubMedGoogle Scholar
  11. Breimer, D.D.: Pharmacokinetics and metabolism of various benzodiazepines used as hypnotics. British Journal of Clinical Pharmacology 8(Suppl. 1): 7S–13S (1979).PubMedGoogle Scholar
  12. Breimer, D.D.; Jochemsen, R. and von Albert, H.H.: Pharmacokinetics of benzodiazepines: Short-acting versus long-acting. Arzneimittel-Forschung 30: 875–881 (1980).PubMedGoogle Scholar
  13. Castledon, CM.; George, C.F.; Mercer, D. and Hallett, C: Increased sensitivity to nitrazepam in old age. British Medical Journal 1: 10–12 (1977).Google Scholar
  14. Chatwin, J.C. and Johns, W.L.: Triazolam: An effective hypnotic in general practice. Current Therapeutic Research 21: 207–214 (1977).PubMedGoogle Scholar
  15. Cloos, F.; Creteur, R.; Defesche, C; Depamelaere, J.; Deweer, E.; Henrotin, J.; Lamboray, R.; Louchez, J.; Peeters, W.; Schiltz, L.; Thiry, J.; van Gerven, J. and Decoster, J.M.: Randomized double-blind cross-over patient preference studies comparing triazolam versus nitrazepam in insomnia. Acta Therapeutica 3: 73–89 (1977).Google Scholar
  16. Corrigan, O.I.: An analysis of the prescribing of certain hypnotics, sedatives and minor tranquillizers among general medical services patients. Journal of the Irish Medical Association 73: 295–299 (1980).PubMedGoogle Scholar
  17. Costa, E.: Benzodiazepines and neurotransmitters. Arzneimittel-Forschung 30: 858–861 (1980).PubMedGoogle Scholar
  18. Dharma, A.P.: Triazolam. Drugs of Today 15: 27–33 (1979).Google Scholar
  19. Deberdt, R.: Triazolam, a benzodiazepine hypnotic used continuously for one year: Further communication. Current Therapeutic Research 28: 31–33 (1980).Google Scholar
  20. Dement, W.; Henry, P. and Cohen, H.: Studies on the effect of REM deprivation in humans and in animals. Research Publications of the Association for Research in Nervous and Mental Diseases 45: 456–468 (1967).Google Scholar
  21. Devenyns, F.: Hypnotic effect of triazolam in geriatric patients: Optimal dose finding study and long term use. Acta Therapeutica 7: 135–150 (1981).Google Scholar
  22. Devroey, P.; Decoster, J.M.; Caudron, J. and Verschueren, G.: Double-blind randomized placebo controlled study, comparing different strengths of triazolam in post-partum patients. Acta Therapeutica 5: 245–257 (1979).Google Scholar
  23. Dordain, G.; Puech, A.J. and Simon, P.: Triazolam compared with nitrazepam and with oxazepam in insomnia: Two double-blind, crossover studies analysed sequentially. British Journal of Clinical Pharmacology 11: 435–495 (1981).Google Scholar
  24. Dukes, M.N.G.: The van der Kroef syndrome; in Dukes (Ed.) Side Effects of Drugs Annual 4, pp.V–IX (Excerpta Medica, Amsterdam, 1980).Google Scholar
  25. Eberts, F.S., Jr.: Comparative metabolism of triazolam, a new sedative-hypnotic, in rat, dog and man. Pharmacologist 16: 196 (1974).Google Scholar
  26. Eberts, F.S., Jr.: Disposition of triazolam, 8-chloro-6-(o-chloro-phenyl)-1-methyl-4H-s-triazolo [4,3-a][1,4] benzodiazepine, in the dog. Drug Metabolism and Disposition 5: 547–555 (1977).PubMedGoogle Scholar
  27. Eberts, F.S., Jr. and Baczinsky, L.: Metabolism of clorazolam, a new sedative-hypnotic, in the dog. Federation Proceedings 32: 747 (1973).Google Scholar
  28. Eberts, F.S., Jr.; Philopoulos, Y.; Reineke, L.M. and Vliek, R.W.: Triazolam disposition. Clinical Pharmacology and Therapeutics 29: 81–93 (1981).PubMedGoogle Scholar
  29. Elliott, H.W.; Navarro, G.; Kokka, N. and Nomof, N.: Early phase I evaluation of sedatives, hypnotics or minor tranquilizers; in Kagan (Ed.) Hypnotics, Methods of Development and Evaluation, pp.87–108 (Spectrum Publications, Holliswood 1975).Google Scholar
  30. Fabre, L.F., Jr.; Brachfeld, J.; Meyer, L.R.; Slowe, I.A.; Calvo, R. and Metzler, C.: Multi-clinic double-blind comparison of triazolam (Halcion®) and placebo administered for 14 consecutive nights in outpatients with insomnia. Journal of Clinical Psychiatry 7: 679–682 (1978a)Google Scholar
  31. Fabre, L.F., Jr.; Gainey, A.; Kemple, S.; McLendon, D.M. and Metzler, C.M.: Pilot open-label study of triazolam in the treatment of insomnia following alcohol withdrawal. Journal of Studies on Alcohol 38: 2188–2192 (1977a).PubMedGoogle Scholar
  32. Fabre, L.F., Jr.; Gross, L.; Pasigajen, V. and Metzler, C.: Multiclinic double-blind comparison of triazolam and flurazepam for seven nights in outpatients with insomnia. Journal of Clinical Pharmacology 17: 402–409 (1977b).PubMedGoogle Scholar
  33. Fabre, L.F., Jr.; McLendon, D.M. and Harris, R.T.: Preference studies of triazolam with standard hypnotics in outpatients with insomnia. Journal of International Medical Research 4: 247–254 (1976).PubMedGoogle Scholar
  34. Fabre, L.F., Jr.; McLendon, D.M. and Purpura, R.: Comparison of triazolam, diazepam and placebo in treatment of insomnia and anxiety in outpatients with anxiety neurosis. Paper presented at the Seventh Annual Meeting of the American College of Clinical Pharmacology, San Francisco, April (1978b).Google Scholar
  35. Fabre, L.F., Jr. and Metzler, CM.: Comparison of 0.25mg of triazolam with 30mg of flurazepam in the treatment of insomnia. Clinical Therapeutics 1: 339–347 (1978).Google Scholar
  36. Fabre, L.F., Jr. and Smith, W.T.: Multi-clinic cross-over comparison of triazolam (Halcion®) and placebo in the treatment of co-existing insomnia and anxiety in anxious outpatients. Diseases of the Nervous System 6: 487–491 (1977).Google Scholar
  37. Forrest, W.H. and Brown, C.R.: Annual report of V.A. cooperative analgesic studies, presented at the 35th National Research Council Committee on Problems of Drug Dependence Meeting, May 21–23 (1973).Google Scholar
  38. Freemon, F.R.; Al-Marashi, M.S.H. and Lee, J.C.M.: The effect of a new benzodiazepine on the polygraphically monitored sleep of normal volunteers. Journal of Clinical Pharmacology 17: 398–401 (1977).PubMedGoogle Scholar
  39. Gall, M.; Hester, J.B. Jr.; Rudzik, A.D. and Lahti, R.A.: Synthesis and pharmacology of novel anxiolytic agents derived from 2-[(Dialkylamino)-methyl-4H-triazol-4-yl] benzophenones and related heterocyclic benzophenones. Journal of Medicinal Chemistry 19: 1057–1064 (1976).PubMedGoogle Scholar
  40. Gomita, Y.; Gomita, H.; Nakaebisu, H.; Kataoka, Y. and Ueki, S.: Effects of the benzodiazepine derivative triazolam on conditioned behavior. Folia Pharmacologica Japonica 74: 615–628 (1978).PubMedGoogle Scholar
  41. Gottschalk, L.A. and Elliott, H.W.: Effects of triazolam and flurazepam on emotions and intellectual function. Research Communications in Psychology, Psychiatry and Behaviour 1: 575–595 (1976).Google Scholar
  42. Greenblatt, D.J.; Allen, M.D. and Shader, R.I.: Toxicity of high-dose flurazepam in the elderly. Clinical Pharmacology and Therapeutics 21: 355–361 (1977).PubMedGoogle Scholar
  43. Hare, S.A.: A comparison of three benzodiazepine hypnotics as oral pre-anaesthetic medication. South African Medical Journal 49: 1883–1884 (1975).PubMedGoogle Scholar
  44. Hartmann, E.: Pharmacological studies of sleep and dreaming: Chemical and clinical relationships. Biological Psychiatry 1: 243–258 (1969).PubMedGoogle Scholar
  45. Heinzl, H.; Axhausen, Ch.; Bähler, U. and Gehrer, H.: Wirkungsvergleich von Triazolam (Halcion) und Flunitrazepam (Rohyprol) in der praoperativen Vorbereitungzeit. Schweizerische Medizinische Wochenschrift 110: 1745–1748 (1980).PubMedGoogle Scholar
  46. Hindmarch, I. and Clyde, C.A.: The effects of triazolam and nitrazepam on sleep quality, morning vigilance and psychomotor performance. Arzneimittel-Forschung 30: 1163–1166 (1980).PubMedGoogle Scholar
  47. Hollister, LE.: Hypnotics; in Clinical Pharmacology of Psychotherapeutic Drugs, p.54 (Churchill Livingstone, New York 1978).Google Scholar
  48. Hollister, L.E.: Psychiatric disorders; in Avery (Ed.) Drug Treatment, 2nd ed., pp. 1057–1121 (ADIS Press, Sydney; Churchill Livingstone, Edinburgh 1980).Google Scholar
  49. Hörig, C; Klotzbach, M.; Koch, H.; Mayr, E. and Richter, J.: Fortschritte auf dem Gebiet der Arzneimittelentwicklung. Pharmazie 31: 497–584 (1976).Google Scholar
  50. Itil, T.M.: Discrimination between some hypnotic and anxiolytic drugs by computer-analyzed sleep; in Williams and Karacan (Eds) Pharmacology of Sleep, p.225 (John Wiley and Sons, New York 1976).Google Scholar
  51. Itil, T.M.; Saletu, B. and Marasa, J.: Digital computer analyzed sleep electroencephalogram (sleep prints) in predicting anxiolytic properties of clorazepate dipotassium (Tranxene). Current Therapeutic Research 14: 415–427 (1972).PubMedGoogle Scholar
  52. Itil, T.M.; Saletu, B. and Marasa, J.: Determination of drug-induced changes in sleep quality based on digital computer ‘sleep prints’. Pharmakopsychiatrie Neuro-Psychopharmakologie 240: 265–280 (1974).Google Scholar
  53. Jochemsen, R.; van Boxtel, CJ. and Breimer, D.D.: Pharmacokinetics of five benzodiazepine hypnotics in the same panel of healthy volunteers; in Aiache and Hirtz (Eds) Proceedings of the 1st European Congress of Biopharmaceutics and Pharmacokinetics (Librairie Lavoisier, Paris, in press 1981).Google Scholar
  54. Johns, M.W.: Sleep and hypnotic drugs. Drugs 9: 448–478 (1975).PubMedGoogle Scholar
  55. Johnson, G.A.; Kim, E.G. and Boukma, S.J.: 6-Phenyl-4H-s-triazolo (4,3-a) (1,4) benzodiazepines: Effect upon catecholamines in rat brain stem. Pharmacologists 13: 234 (1971).Google Scholar
  56. Kales, A.; Bixler, E.O.; Kales, J.D. and Scharf, M.B.: Comparative effectiveness of nine hypnotic drugs: Sleep laboratory studies. Journal of Clinical Pharmacology 17: 207–213 (1977).PubMedGoogle Scholar
  57. Kales, A.; Kales, J.D.; Bixler, E.O.; Scharf, M.B. and Russek, E. Hypnotic efficacy of triazolam: Sleep laboratory evaluation of intermediate-term effectiveness. Journal of Clinical Pharmacology 16: 399–406 (1976).PubMedGoogle Scholar
  58. Kay, DC; Blackburn, A.B.; Buckingham, J.A. and Karacan, I.: Human pharmacology of sleep; in Williams and Karacan (Eds) Pharmacology of Sleep, pp.83–103 (John Wiley and Sons, New York 1976).Google Scholar
  59. Keighley, M.R.B.; Gannon, M.; Warlow, J.; Jenkins, C.R.M. and Gammon, R.J.: Evaluation of single-dose hypnotic treatment before elective operation. British Medical Journal 281: 829–831 (1980).PubMedGoogle Scholar
  60. Kitagawa, H.; Esumi, Y.; Kurosawa, S.; Sekine, S. and Yokoshima, T.: Metabolism of 8-chloro-6-(o-chloropenyl)-1-methyl-4H-s-triazolo [4,3-a] [1,4] benzodiazepine, triazolam, a new central depressant. I. Absorption, distribution and excretion in rats, dogs and monkeys. Xenobiotica 9: 415–428 (1979a).PubMedGoogle Scholar
  61. Kitagawa, H.; Esumi, Y.; Kurosawa, S.; Sekine, S. and Yokoshima, T.: Metabolism of 8-chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo [4,3-a] [1,4] benzodiazepine, triazolam, a new central depressant. II. Identification and determination of metabolites in rats and dogs. Xenobiotica 9: 429–439 (1979b).PubMedGoogle Scholar
  62. Knapp, R.B.; Boyd, E.L.; Linsenmeyer, G. and Linet, O.I.: Evaluation of triazolam, flurazepam, and placebo as hypnotic agents in pre-surgical patients. Current Therapeutic Research 23: 230–235 (1978).Google Scholar
  63. Knapp, R.B.; Tercan, E.; Remen, D and Linsenmeyer, G.: Evaluation of triazolam, flurazepam, and placebo as hypnotic agents in pre-surgical patients. Proceedings of the 6th World Congress of Anesthesiology, Mexico City, April 26–30, 1976, pp.205–206 (Excerpta Medica/International Congress Series No 387, Amsterdam 1976).Google Scholar
  64. Knobel, M.: Hypnotic effect of triazolam. Revista Brasileira de Medicina 36: 518–524 (1979).Google Scholar
  65. Kusaka, M.; Horikawa, A.; Meshi, T. and Maruyama, Y.: Interaction of triazolam with desipramine. Psychopharmacology 70: 255–261 (1980).PubMedGoogle Scholar
  66. Lackner, H. and Hunt, V.E.: The effect of Librium on hemostasis. American Journal of Medical Science 256: 368–372 (1968).Google Scholar
  67. Lahti, R.A. and Barsuhn, C: The effect of minor tranquilizers on stress-induced increases in rat plasma corticosteroids. Psychopharmacologia 35: 215–220 (1974).PubMedGoogle Scholar
  68. Lasagna, L.: The Halcion story: Trial by media. Lancet 1: 815–816 (1980).PubMedGoogle Scholar
  69. Leibowitz, M. and Sunshine, A.: Long-term hypnotic efficacy and safety of triazolam and flurazepam. Journal of Clinical Pharmacology 18: 302–309 (1978).PubMedGoogle Scholar
  70. Linet, O.I. and Rudzik, A.D.: Comparison of triazolam and methyprylon as a hypnotic in insomniacs. Psychopharmacology Communications 1: 473–480 (1975).PubMedGoogle Scholar
  71. Lipani, J.A.: Preference study of the hypnotic efficacy of triazolam 0.125mg compared to placebo in geriatric patients with insomnia. Current Therapeutic Research 24: 397–402 (1978).Google Scholar
  72. Lomen, P. and Linet, O.I.: Hypnotic efficacy of triazolam and methyprylon in insomniac in-patients. Journal of International Medical Research 4: 55–58 (1976).PubMedGoogle Scholar
  73. Mackerer, C.R.; Kochman, R.L.; Bierschenk, B.A. and Bremner, S.S.: The binding of [3H] diazepam to rat brain homogenates. Journal of Pharmacology and Experimental Therapeutics 206: 405–413 (1978).PubMedGoogle Scholar
  74. MacLeod, N. and Kratochvil, C.H.: Behavioural reactions to triazolam. Lancet 2: 638–639 (1979).PubMedGoogle Scholar
  75. Matta, B.; Franco, A.E.; Le Zotte, L.A.; Rudzik, A.D. and Veldkamp, W.: Comparison of triazolam, flurazepam and placebo as hypnotic agents in pre-surgical patients. Current Therapeutic Research 16: 958–963 (1974).PubMedGoogle Scholar
  76. Mendelson, W.B.; Goodwin, D.W.; Hill, S.Y. and Reichman, J.D.: The morning after: Residual EEG effects of triazolam and flurazepam, alone and in combination with alcohol. Current Therapeutic Research 19: 155–163 (1976).PubMedGoogle Scholar
  77. Metzler, CM.; Ko, H.; Royer, M.E.; Veldkamp, W. and Linet, O.I.: Bioavailability and pharmacokinetics of orally administered triazolam in normal subjects. Clinical Pharmacology and Therapeutics 21: 111–112 (1977).Google Scholar
  78. Moffett, R.B.: New benzodiazepine analogues: Synthesis and CNS activity. Journal of Heterocyclic Chemistry 3(Suppl.): S123–S130 (1976).Google Scholar
  79. Monier, H. and Okada, T.: Biochemical identification of the site of action of benzodiazepines in human brain by 3H-diazepam binding. Life Sciences 22: 985–996 (1978).Google Scholar
  80. Nakazawa, K.; Umajima, I.; Hazama, H.; Komuku, C; Umezawa, Y. and Akamatsu, T.: Effects of triazolam on sleep examined by 24-hour polygraphy-comparison with nitrazepam and flurazepam. Clinical Psychiatric Medicine 6 (Suppl.): 1415–1425 (1977).Google Scholar
  81. Nicholson, A.N.: Hypnotics: Rebound insomnia and residual sequelae. British Journal of Clinical Pharmacology 9: 223–225 (1980).PubMedGoogle Scholar
  82. Nicholson, A.N. and Stone, B.M.: Activity of the hypnotics, flunitrazepam and triazolam, in man. British Journal of Clinical Pharmacology 9: 187–194 (1980).PubMedGoogle Scholar
  83. Ogata, H. and Gomita, Y.: Effects of various psychotropic drugs on intracranial self-stimulation behavior in rats. Japanese Journal of Pharmacology 26 (Suppl.): 40P (1976).Google Scholar
  84. Ogura, C; Nakazawa, K.; Majima, K.; Nakamura, K.; Ueda, H.; Umezawa, Y. and Wardell, W.M.: Residual effects of hypnotics: Triazolam, flurazepam and nitrazepam. Psychopharmacology 68: 61–65 (1980).PubMedGoogle Scholar
  85. Okawa, K.K.: Comparison of triazolam 0.25mg and flurazepam 15mg in treating geriatric insomniacs. Current Therapeutic Research 23: 381–387 (1978).Google Scholar
  86. Okawa, K.K. and Allen, G.S.: A clinical comparison of triazolam with placebo and with secobarbital in insomniac patients. Journal of International Medical Research 6: 343–347 (1978).PubMedGoogle Scholar
  87. Okuma, T. and Honda, H.: Model insomnia, noise, and methylphenidate, used for the evaluation of hypnotic drugs. Psychopharmacology 57: 127–132 (1978).PubMedGoogle Scholar
  88. Orme, M.; Breckenridge, A. and Brooks, R.V.: Interactions of benzodiazepines with warfarin. British Medical Journal 3: 611–614 (1972).PubMedGoogle Scholar
  89. Oswald, I.: Psychological medicine. Sleep difficulties. British Medical Journal 1: 557–558 (1975).PubMedGoogle Scholar
  90. Pegram, V.; Hyde, P. and Linton, P.: Chronic use of triazolam: The effects on the sleep patterns of insomniacs. Journal of International Medical Research 8: 224 (1980).PubMedGoogle Scholar
  91. Phillips, C.T. and Wilson, R.D.: A comparison of triazolam and pentothal as an induction agent in dogs. Federation Proceedings 33: 509 (1974).Google Scholar
  92. Phillips, M.T. and Wilson, R.D.: Comparative studies of cardiopulmonary effects of two parenteral benzodiazepines. Federation Proceedings 33: 510 (1974).Google Scholar
  93. Piccione, P.; Zorick, F.; Lutz, T.; Grissom, T.; Kramer, M. and Roth, T.: The efficacy of triazolam and chloral hydrate in geriatric insomniacs. Journal of International Medical Research 8: 361–367 (1980).PubMedGoogle Scholar
  94. Puech, A.J.; Dordain, G.; Hecguet, S.; Paturand, J.-P. and Simon, P.: Etude croisée en double avengle effectuée pan des omnipraticiens comparant triazolam et nitrazépam chez des insomniaques. Therapie 33: 287–292 (1978).PubMedGoogle Scholar
  95. Reeves, R.L.: Comparison of triazolam, flurazepam, and placebo as hypnotics in geriatric patients with insomnia. Journal of Clinical Pharmacology 17: 319–323 (1977).PubMedGoogle Scholar
  96. Reynaert, J.: Triazolam als slaapmiddel bij psychiatrische Patienten. Acta Therapeutica 6: 75–85 (1980).Google Scholar
  97. Rickels, K.; Gingrich, R.L.; Morris, R.J.; Rosenfeld, H. and Perloff, M.M.: Triazolam in insomniac family practice patients. Clinical Pharmacology and Therapeutics 18: 315–324 (1975).PubMedGoogle Scholar
  98. Ristola, P.; Pyorala, K.; Jalonen, K. and Suhonen, O.: The effect of diazepam on the rate of warfarin metabolism in man, rabbit, and rat. Scandinavian Journal of Clinical and Laboratory Investigation 27(Suppl. 116): 18–22 (1971).Google Scholar
  99. Robinson, D.S. and Amidon, E.L.: Interaction of benzodiazepines with warfarin in man; in Garattini et al. (Eds) The Benzodiazepines, pp.641–646 (Raven Press, New York 1973).Google Scholar
  100. Roth, T.; Hartse, K.M.; Saab, P.G.; Piccione, P.M. and Kramer, M.: The effects of flurazepam, lorazepam, and triazolam on sleep and memory. Psychopharmacology 70: 231–237 (1980).PubMedGoogle Scholar
  101. Roth, T.; Kramer, M. and Lutz, T.: Intermediate use of triazolam: A sleep laboratory study. Journal of International Medical Research 4: 59–63 (1976).PubMedGoogle Scholar
  102. Roth, T.; Kramer, M. and Lutz, T.: The effects of triazolam (0.25mg) on the sleep of insomniac subjects. Drugs and Experimental Clinical Research 1: 271–277 (1977a).Google Scholar
  103. Roth, T.; Kramer, M. and Lutz, T.: The effects of hypnotics on sleep, performance, and subjective state. Drugs and Experimental Clinical Research 1: 279–286 (1977b).Google Scholar
  104. Roth, T.; Kramer, M. and Schwartz, J.L.: Triazolam: A sleep laboratory study of a new benzodiazepine hypnotic. Current Therapeutic Research 16: 117–123 (1974).PubMedGoogle Scholar
  105. Rudzik, A.D.; Hester, J.B. and Friis, W.: Pharmacologic activity of a series of 6-Phenyl-4H-s-triazolo [4,3-a] [1,4] benzodiazepines in mice. Pharmacologist 13: 205 (1971).Google Scholar
  106. Saletu, B.: Psychopharmaka und die Schlafqualität: Quantitative neurophysiologische und subjektive Parameter. Arzneimittel-Forschung 26: 1042–1047 (1976).PubMedGoogle Scholar
  107. Sellers, E.M.: Clinical pharmacology and therapeutics of benzodiazepines. Canadian Medical Association Journal 118: 1533–1538 (1978).PubMedGoogle Scholar
  108. Sethy, V.H.: Effect of hypnotic and anxiolytic agents on regional concentration of acetylcholine in rat brain. Naunyn-Schmiedeberg’s Archives of Pharmacology 301: 157–161 (1978).PubMedGoogle Scholar
  109. Sethy, V.H. and Solomon, C.A.: Effect of hypnotics and anti-anxiety drugs on acetylcholine (Ach) concentrations in discrete areas of the rat brain. Pharmacologist 19: 234 (1977).Google Scholar
  110. Shibuya, T.; Sato, K.; Matsuda, H.; Nishimori, T.; Hayashi, M.; Nomura, K. and Chen, P.C.: Effects of benzodiazepines on brain monoamines. Japanese Journal of Pharmacology 26 (Suppl.): 102P (1976).Google Scholar
  111. Shugars, K.D.; Linet, O.I.; Metzler, CM. and Rudzik, A.D.: A multiclinic comparison of the hypnotic efficacy of triazolam and placebo in insomniac outpatients. Clinical Therapeutics 2: 390–398 (1980).Google Scholar
  112. Singh, A.N. and Saxena, B.: Double-blind crossover comparison of triazolam and flurazepam in hospitalizedpsychiatric patients with insomnia. Current Therapeutic Research 27: 627–633 (1980).Google Scholar
  113. Speth, R.C; Wastek, G.J.; Johnson, P.C. and Yamamura, H.I.: Benzodiazepine binding in human brain: Characterization using [3H] flunitrazepam. Life Sciences 22: 859–866 (1978).PubMedGoogle Scholar
  114. Stein, L.: Behavioural neurochemistry of benzodiazepines. Arzneimittel-Forschung 30: 868–874 (1980).PubMedGoogle Scholar
  115. Straw, R.N.: Pharmacological evaluation of hypnotic drugs in infrahuman species as related to clinical utility; in Kagan (Ed.) Hypnotics, Methods of Development and Evaluation, pp.65–85 (Spectrum Publications, Holliswood 1975).Google Scholar
  116. Tanabe, K.; Kinoshita, Y.; Tamaki, H. and Kimizima, K.: Actio of triazolam on central nerve; translation of paper presented at the 28th Seinan Regional Meeting of JPS, Nagasaki City (1978).Google Scholar
  117. Tideisaar, R.: Drugs and the elderly. Canadian Medical Association Journal 119: 415–416 (1978).Google Scholar
  118. Tuchmann-Duplessis, H.: Effect of the benzodiazepines on offspring. Revue de Médecine 37: 2013–2023 (1976).Google Scholar
  119. Ueki, S.; Watanake, S.; Fujiwara, M.; Yamamoto, T.; Araki, H. and Omori, K.: Behavioral and electroencephalographic studies of the new benzodiazepine derivative triazolam. Folia Pharmacologica Japonica 74: 597–614 (1978).PubMedGoogle Scholar
  120. van der Kroef, C; Halcion: A harmless hypnotic? Nederlands Tijdschrift voor Gengeeskunde 123: 1160–1162 (1979a).Google Scholar
  121. van der Kroef, C: Reactions to triazolam. Lancet 2: 526 (1979b).PubMedGoogle Scholar
  122. Veldkamp, W.; Straw, R.N.; Metzler, C.M. and Demissiamos, H.V.: Efficacy and residual effect evaluation of a new hypnotic, triazolam. Journal of Clinical Pharmacology 14: 102–111 (1974).PubMedGoogle Scholar
  123. Vergute, L.; Huyghebaert, G. and Corveleyn, P.: Een vergelijkende studie tussen twee slaapmiddelen: Triazolam en nitrazepam. Acta Therapeutica 4: 5–14 (1978).Google Scholar
  124. Vogel, G.W.; Barker, K.; Gibbons, P. and Thurmond, A.: A comparison of the effects of flurazepam 30mg and triazolam 0.5mg on the sleep of insomniacs. Psychopharmacology 47: 81–86 (1976).PubMedGoogle Scholar
  125. Vogel, G.W.; Thurmond, A.; Gibbons, P.; Edwards, K.; Sloan, K.B. and Sexton, K.: The effect of triazolam on the sleep of insomniacs. Psychopharmacologia 41: 65–69 (1975).PubMedGoogle Scholar
  126. Walters, A.J. and Lader, M.M.: Hangover effect of hypnotics in man. Nature 229: 637–638 (1971).PubMedGoogle Scholar
  127. Walther, M.: Ein beitrag zur Behandlung von Schlafstörungen mit dem neuen Benzodiazepine Triazolam. Schweizerische Rundschau für Medizin 69: 460–467 (1980).Google Scholar
  128. Wang, R.I.H. and Stockdale, S.L. The hypnotic efficacy of triazolam. Journal of International Medical Research 1: 600–607 (1973).Google Scholar
  129. Wang, R.I.H.; Wilbur, M. and Hieb, E.: Determining optimum dose and acute tolerance of triazolam. Journal of International Medical Research 5: 184–190 (1977).PubMedGoogle Scholar
  130. Watanabe, I.; Fujiwara, M.; Yamamoto, K.; Araki, H.; Ohmori, K. and Ueki, S.: Behavioral pharmacology and brain wave study on triazolam, a new benzodiazepine derivative. Translation of a paper presented at the 28th Seinan Regional Meeting of JPS, Nagasaki City (1978).Google Scholar
  131. Westerholm, B.; Kristensen, F.; Schaffalitzky de Muckadell, H.V.; Idänpään-Heikkilä, J.; Lahti, T.; Grimsson, A.; Olaffson, O.; McMeekin, C; Lunde, P.K.M. and Oydvin, K.: Drug utilization — geographical differences and clinical implications — psychotropic drugs. Advances in Pharmacology and Therapeutics 6: 113–121 (1979).Google Scholar

Copyright information

© ADIS Press Australasia Pty Ltd 1981

Authors and Affiliations

  • G. E. Pakes
    • 1
  • R. N. Brogden
    • 1
  • R. C. Heel
    • 1
  • T. M. Speight
    • 1
  • G. S. Avery
    • 1
  1. 1.Australasian Drug Information ServicesBirkenhead, Auckland 10New Zealand

Personalised recommendations